Tokushima University / Educator and Researcher Directory --- Yoshida, Tomohiro

Search:

Tokushima University ⟩ University Hospital ⟩ Clinical Division ⟩ Department of Neurosurgery, Psychiatry and Anesthesiology ⟩ Psychiatry ⟩
Tokushima University ⟩ University Hospital ⟩ Clinical Division ⟩ Department of Neurosurgery, Psychiatry and Anesthesiology ⟩ Psychosomatic Medicine ⟩

(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Toshiyuki Shirai, Satoshi Okazaki, Takaki Tanifuji, Shusuke Numata, Tomohiko Nakayama, Tomohiro Yoshida, Kentaro Mouri, Ikuo Otsuka, Noboru Hiroi and Akitoyo Hishimoto : Meta-analyses of epigenetic age acceleration and GrimAge components of schizophrenia or first-episode psychosis., Schizophrenia, 10, 1, 108, 2024. (Summary) Schizophrenia is a common chronic psychiatric disorder that causes age-related dysfunction. The life expectancy in patients with schizophrenia is 10 years shorter than that in the general population because of the higher risk of other diseases, such as cardiovascular diseases. Aging studies based on DNA methylation status have received considerable attention. Several epigenetic age accelerations and predicted values of aging-related proteins (GrimAge and GrimAge2 components) have been analyzed in multiple diseases. However, no studies have investigated up to GrimAge and GrimAge2 components between patients with schizophrenia and controls. Therefore, we aimed to conduct multiple regression analyses to investigate the association between schizophrenia and epigenetic age accelerations and GrimAge and GrimAge2 components in seven cohorts. Furthermore, we included patients with first-episode psychosis whose illness duration was often shorter than schizophrenia in our analysis. We integrated these results with meta-analyses, noting the acceleration of GrimAge, GrimAge2, and DunedinPACE, and increase in adrenomedullin, beta-2 microglobulin, cystatin C, and plasminogen activation inhibitor-1 levels, in patients with schizophrenia or first-episode psychosis. These results corroborated the finding that patients with schizophrenia had an increased risk of diabetes, cardiovascular disease, and cognitive dysfunction from a biological perspective. Patients with schizophrenia and first-episode psychosis showed differences in the results when compared with controls. Such analyses may lead to the development of novel therapeutic targets to patients with schizophrenia or relevant diseases from the perspective of aging in the future. (Link to Publication Site) ● Publication site (DOI): 10.1038/s41537-024-00531-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39548083 ● Search Scopus @ Elsevier (PMID): 39548083 ● Search Scopus @ Elsevier (DOI): 10.1038/s41537-024-00531-8 (DOI: 10.1038/s41537-024-00531-8, PubMed: 39548083)
2.	Tomoya Takeda, Hidehiro Umehara, Yui Matsumoto, Tomohiro Yoshida, Masahito Nakataki and Shusuke Numata : Schizophrenia and cognitive dysfunction., The Journal of Medical Investigation : JMI, 71, 3.4, 205-209, 2024. (Summary) Schizophrenia is a psychiatric disorder with cognitive dysfunction as a core symptom along with positive and negative symptoms. Cognitive dysfunction in schizophrenia can be broadly classified into neurocognitive and social cognitive deficits, with these deficits significantly influencing social functioning. Therapeutic interventions aiming to enhance neurocognition and social cognition have been developed. In this review, we describe the characteristics of cognitive dysfunction in patients with schizophrenia, its relationship to social function, and intervention strategies. J. Med. Invest. 71 : 205-209, August, 2024. (Keyword) Humans / Cognitive Dysfunction / schizophrenia / Schizophrenic Psychology (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.71.205 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39462553 ● Search Scopus @ Elsevier (PMID): 39462553 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.71.205 (DOI: 10.2152/jmi.71.205, PubMed: 39462553)

Proceeding of Domestic Conference:

1.	Yui Matsumoto, Masahito Nakataki, 石本良祐, 一宮俊文, 野田尚吾, 前田拓也, 増田太利志, Tomohiro Yoshida, Shun Aoi, Naoki Yamada, Yukiko Tomioka, Hidehiro Umehara, 土師正太郎, Koji Fujita, Yuishin Izumi and Shusuke Numata : ADの灰白質体積と神経心理検査および髄液アミロイドβの関連性の検討, 【第42回日本認知症学会学術総会, Nov. 2023.
2.	Yui Matsumoto, Masahito Nakataki, 石本良祐, 一宮俊文, 野田尚吾, 前田拓也, 増田太利志, Tomohiro Yoshida, Shun Aoi, Naoki Yamada, Yukiko Tomioka, Hidehiro Umehara, 土師正太郎, Koji Fujita, Yuishin Izumi and Shusuke Numata : 認知症の灰白質体積と神経心理検査および髄液アミロイドβの関連性の検討, 第45回日本生物学的精神医学会年会, Nov. 2023.
3.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, Yui Matsumoto, Tomohiro Yoshida, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Akira Takahashi, 岡本泰昌 and Shusuke Numata : 大うつ病性障害患者における治療前後の血中代謝物濃度の変化, 第45回日本生物学的精神医学会年会, Nov. 2023.
4.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, Yui Matsumoto, Tomohiro Yoshida, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Akira Takahashi, 岡本泰昌 and Shusuke Numata : 双極性障害における血中代謝物の変化, 第33回日本臨床精神神経薬理学会学術集会, Sep. 2023.